NewsRelease
ResearchArticle Cites Viraffinity™ for Dengue Virus (DV) Purification
MONMOUTHJUNCTION, NJ, July27, 2016 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their virusenrichment technology for viral proteomic analyses from plasma.
Thecitation is:
RomainFragnoud, Marie Flamand, Frederic Reynier, Philippe Buchy, VasnaDuong, Alexandre Pachot, Glaucia Paranhos-Baccala and Frederic Bedin.Differentialproteomic analysis of virus enriched fractionsobtained from plasma pools of patients with dengue fever or severedengue.BMC Infectious Diseases (2015) 15:518.http://www.ncbi.nlm.nih.gov/pubmed/26572220
Inbrief, the article’s authors report a method to compare theproteomes of virion-enriched fractions purified from plasma pools ofpatients with dengue fever or severe dengue. Virions were purified byultracentrifugation combined with Viraffinity™.Following in-gel hydrolysis, peptides were analyzed by LC-MS. Thearticle states “A technique based on ultracentifugation (Step 1)followed by concentration using…Viraffinity™,was created to obtain a fraction of plasma enriched with DVparticles. A positive signal corresponding to monomeric (60 kDa) anddimeric E protein (120 KDa) was observed in the DV-infected samples,and became more intense after the Viraffinity™step…Densitometry indicated that the protein complexity of thepurified samples was reduced by roughly 350-fold compared to theunpurified samples.”. The authors conclude that the Viraffinity™based technique of virion-enrichment allowed them to identify twohost proteins that have prognostic value for classifying patientswith acute dengue who are more likely to develop a severe dengue.
“Weare very happy to see that not only is Viraffinity™useful in LC-MS proteomics, but that it complements the gold-standardof enrichment using gradient ultracentrifugation. I am very pleasedthat the exquisite selectivity profile of Viraffinity™was in-part the reason these researchers were able to enrich viralproteomes 350-fold from plasma!” states Swapan Roy, Ph.D.,President and Founder of Biotech Support Group.
For more information visit: Viraffinity™ at
http://www.biotechsupportgroup.com/Viraffinity-Virus-and-Viral-Component-Isolation-p/v1062.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, goto http://www.biotechsupportgroup.com
Contact:
Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
[email protected]
http://www.biotechsupportgroup.com
